What is Achieve Life Sciences's stock-based comp?

Achieve Life Sciences (ACHV) reported stock-based comp of -$685K in Q1 2026.

How has Achieve Life Sciences's stock-based comp changed year-over-year?

Achieve Life Sciences's stock-based comp decreased by 130.7% year-over-year, from $2.23M to -$685K.

Over 4 years (2021 to 2025), Achieve Life Sciences's stock-based comp has grown at a 41.5% compound annual growth rate (CAGR), from $2.19M to $8.76M.

PfizerPFE

——

Net income-$10.2M+20.7%

EPS (diluted)-$0.19+48.6%

Cash & equivalents$28.1M+116%

Total debt$5.6M+332%

Total equity$10.7M+3.9%

Total assets$33.1M+21.0%

Operating cash flow-$6.9M+37.5%

CapEx$750.0—

Free cash flow-$12.4M—

Market cap$585.16M+404%

Enterprise value$562.71M+439%

Return on equity-496.1%-906pp

Debt / equity0.5×+0.4×

Current ratio2.6×-0.9×

Reported directly by Achieve Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Achieve Life Sciences’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Achieve Life Sciences's stock-based comp?: Achieve Life Sciences (ACHV) reported stock-based comp of -$685K in Q1 2026.
How has Achieve Life Sciences's stock-based comp changed year-over-year?: Achieve Life Sciences's stock-based comp decreased by 130.7% year-over-year, from $2.23M to -$685K.
What is the long-term trend for Achieve Life Sciences's stock-based comp?: Over 4 years (2021 to 2025), Achieve Life Sciences's stock-based comp has grown at a 41.5% compound annual growth rate (CAGR), from $2.19M to $8.76M.